Navigation Links
New Results From ARTEN Study of Nevirapine Plus Tenofovir and Emtricitabine (TDF/FTC) Versus Boosted Protease Inhibitor Regimen of Atazanavir/Ritonavir Plus TDF/FTC Revealed
Date:7/20/2009

s who received once-daily nevirapine (400 mg). Nevirapine is not indicated for once-daily dosing. The safety and efficacy of once-daily dosing have not been established

Safety/Tolerability Data

In the nevirapine group, the most common adverse event was rash/eruptions/exanthema (16.0 percent). Of the nevirapine-associated rashes that resulted in discontinuation, 76.2 percent (16 of 21) were identified during the two-week lead-in phase. The rate of hepatitis as reported by investigators was 1.6 percent in patients who received once-daily nevirapine, 2.1 percent in patients who received twice-daily nevirapine and 0.0 percent in patients who received ATV/r. Rates of liver enzyme elevations were 5.9 percent in patients who received once-daily nevirapine, 7.4 percent in patients who received twice-daily nevirapine and 1.6 percent in patients who received ATV/r. The rate of serious adverse events seen at 48 weeks in patients was 9.6 percent in the nevirapine group and 8.8 percent in the ATV/r group. Discontinuation due to adverse events was 13.6 percent in the nevirapine arms (51 of 376 patients), and 3.6 percent in the ATV/r arm (7 of 193 patients).(4) These results include patients who received once-daily nevirapine (400 mg). Nevirapine is not indicated for once-daily dosing. The safety and efficacy of once-daily dosing have not been established.

VIRAMUNE Important Safety Information

VIRAMUNE is indicated for use in combination with other antiretroviral agents for the treatment of HIV infection.

VIRAMUNE does not cure HIV or AIDS, and has not been shown to reduce the risk of passing HIV to others through sexual contact or blood contamination.

VIRAMUNE can cause severe liver disease and skin reactions that can cause death. These reactions occur most often during the first 18 weeks of treatment, but can occur later. Patients need t
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
3. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
4. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
5. Tapestry Reports Second Quarter 2007 Results
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
8. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
9. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
10. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... 2014 , The ... hub of information concerning the biopharmaceutical Group,s national and international ... addition to the recently launched institutional website that is receiving ... enriched by a new chapter in the fascinating story of ... detailed and panoramic hub on the world of clinical research, ...
(Date:12/17/2014)... 2014 PCCA received the Autism Hope ... ) program seal for best practices in meeting ... medical practices, materials and goods that meet strict ... Children affected by autism often have unique physical ... ingredients found in food and medicine – for ...
(Date:12/15/2014)... Research and Markets , ... has announced the addition of the "Cardiac Guidewires ... their offering. Global Guidewires sector is projected to ... America accounts for nearly 35% (2015) of ... claims approximately 25% (2018). Asia-Pacific ...
Breaking Medicine Technology:Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 2Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 3Parents Of Children With Autism Spectrum Disorder Have New Options When Administering Medications 2Parents Of Children With Autism Spectrum Disorder Have New Options When Administering Medications 3Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 2Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 3Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 4
(Date:12/17/2014)... -- Expectant parents should leave prenatal picture-taking to medical ... Use of ultrasound imaging and heartbeat monitors to get ... agency warns. "Although there is a lack ... and heartbeat monitors, prudent use of these devices by ... FDA biomedical engineer, said in an agency news release. ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, ... America, and work commitment is a big reason why, new ... said Dr. Mathias Basner, an assistant professor of sleep and ... of Medicine. A time-use survey of nearly 125,000 Americans, ... main activity exchanged for sleep. Short sleepers -- those who ...
(Date:12/15/2014)... 15, 2014 South Florida’s leading urgent care ... can be a daze of hassle, hustle, and bustle that ... decking halls, to burns when making special meals and heartburn ... can happen at any time. To prevent this season of ... made a list of helpful and healthful holiday tips to ...
(Date:12/15/2014)... News) -- Expert pilots process visual information more efficiently ... better decisions during landings, a new study shows. ... pilots to master, and 36 percent of all airplane ... final approach and landing. Researchers monitored the brain ... pilots while they were at the controls of a ...
(Date:12/15/2014)... 15, 2014 At the leading, long-established ... AutismOne and Focus Autism will welcome ... research on the effects of toxins to children’s health, ... information. , Luminaries such as Dr. Lucija Tomljenovic ... with esteemed, credentialed colleagues of the United States to ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:Study Shows Why Expert Pilots Are Experts 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 3
... Amsterdam, June 26, 2008 - Elsevier, the leading ... and services, today announced highlights of its Journal ... Journal Citation Reports published by ThomsonReuters, reports that ... respective categories. In addition, total Elsevier journal citations ...
... to Avastin at Improving Visual Acuity When, Used ... Share, ... Resources, WALTHAM, Mass., June 26 Decision Resources, ... on pharmaceutical and,healthcare issues, finds that Genentech/Novartis,s Lucentis will ...
... One of Canada,s Largest Academic Cancer Centers, ... ARAY ), a global leader in the field ... de Montreal (CHUM),has purchased a CyberKnife(R) Robotic Radiosurgery ... Montreal, Canada., CHUM, one of the largest ...
... Pharmaceuticals, Inc. (Nasdaq: AVRX), announced today the nomination of AVN316 ... Inhibitor program. This novel compound inhibits the Beta-catenin pathway and ... The Company plans to begin clinical testing of AVN316 in ... commonly activated cancer pathways and is known to play a ...
... who eat unhealthy, high-fat meals may experience memory declines ... antioxidant vitamins with the meal, according to new research ... diabetes to cognitive complications in humans. Adults with ... memory deficits after eating unhealthy foods. , This ...
... 2008 Tour Will Donate More than $1.6 Million and ... Dealers Supporting the Fight against Pediatric Cancer, FOUNTAIN ... on Wheels(TM) Tour launched yesterday in Los Angeles with ... Hospital Los,Angeles. The Tour will visit 32 children,s hospitals ...
Cached Medicine News:Health News:Elsevier announces 2007 journal impact factor highlights 2Health News:Because of Its Ability to Generate Higher Total Sales in the United States and Europe, Lucentis Will Earn Clinical Gold Standard Status by 2011 for the Treatment of Diabetic Retinopathy 2Health News:First CyberKnife System to be Installed in Canada 2Health News:First CyberKnife System to be Installed in Canada 3Health News:First CyberKnife System to be Installed in Canada 4Health News:Avalon Pharmaceuticals names lead development candidate in beta-catenin inhibitor program 2Health News:Seniors with type 2 diabetes may experience memory declines immediately after eating unhealthy meal 2Health News:Seniors with type 2 diabetes may experience memory declines immediately after eating unhealthy meal 3Health News:Hyundai Motor America and Its Dealers Launch National Hope on Wheels Tour to Support Pediatric Cancer Research 2Health News:Hyundai Motor America and Its Dealers Launch National Hope on Wheels Tour to Support Pediatric Cancer Research 3
... management software - was designed by ... improvement tool helps diabetes care providers ... bridges medicine with technology by providing ... information technology product. This diabetes ...
... of diabetes in order to maintain tight control ... way to reduce or even prevent diabetes-related complications. ... a diabetes patients quality of life, however, is ... been the guiding factors in the development of ...
... the CGMS System Gold can assist you ... based on detailed glycemic profiles. Its also ... motivation and collaboration with patients.1, ,While ... all diabetes patients, it may be of ...
... The GlucoWatch G2 Biographer is intended for ... levels in adults (aged 18 and older) ... diabetes. Parents should supervise the use of ... G2 Biographer is intended to supplement, not ...
Medicine Products: